Data from The Lancet Gastroenterology & Hepatology showed #benralizumab induces remission in 77% of patients with #eosinophilicgastritis. #GITwitter bit.ly/3Ya49nG
Benralizumab induced histological remission at 12 weeks in more than three-fourths of patients with #eosinophilicgastritis, although other biomarkers of disease persisted, according to data in The Lancet Gastroenterology & Hepatology. Healio Gastroenterology #GITwitter healio.com/news/gastroent…
#Benralizumab induced histological remission at 12 weeks in more than three-fourths of patients with #eosinophilicgastritis, although other biomarkers of disease persisted, according to data in The Lancet Gastroenterology & Hepatology. #GITwitter bit.ly/3Ya49nG
Paradigm challenging research in eosinophilic GI diseases & early data for a potential new treatment for coeliac disease featured in The Lancet Gastroenterology & Hepatology last week A summary 👉 linkedin.com/posts/rob-brie… #GITwitter #CoeliacDisease #CeliacDisease #EosinophilicGastritis
New research - Kliewer et al - Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial thelancet.com/journals/langa… #gitwitter #eosinophilicgastritis Rothenberg CURED Research Lab CURED Foundation
🟪TEENS AND ADULTS AGES 12 TO 70 YEARS OLD WITH EOSINOPHILIC GASTRITIS NEEDED FOR A RESEARCH STUDY *️⃣Contact: [email protected]|513-517-2108 for additional information ➡️www1.rarediseasesnetwork.org/cms/cegir/Get-… #eosinophilicgastritis #eosinophilicdisorder #raredisease
Researchers Assess #Endoscopic Activity for #EosinophilicGastritis Read the study in AJG - The American Journal of Gastroenterology w/Consortium of #Eosinophilic #Gastrointestinal Disease Researchers #CEGIR: journals.lww.com/ajg/Abstract/9…